靶向抗肿瘤抗体-药物偶联物研发进展  

Research and Development Progress of Targeted Antitumor Antibody-Drug Conjugate

作　　者：谢铭[1] 

机构地区：[1]广西民族大学预科教育学院,广西南宁530006

出　　处：《大众科技》2022年第10期113-116,共4页Popular Science & Technology

摘　　要：抗体-药物偶联物(ADC)是将细胞毒性小分子药物与单克隆抗体偶联的靶向抗肿瘤药物,利用抗体的特异靶向性和细胞毒性小分子的高效抗肿瘤活性,达到高效低毒的目的,是当前肿瘤创新药研发的热点。文章主要从单克隆抗体的筛选和人源化改造、靶点抗原的选择、细胞毒小分子的类型、连接子的偶联策略等方面进行综述,对ADC研发趋势进行总结分析,为教学和科研提供参考。Antibody-drug conjugate(ADC) is a targeted antitumor drug that couples cytotoxic small molecule drugs with monoclonal antibodies.Using the specific targeting of antibodies and the high antitumor activity of small cytotoxic molecules,achieve the purpose of high efficiency and low toxicity.It is a hot spot in the research and development of innovative cancer drugs.This paper reviews the screening and humanization of monoclonal antibodies,the selection of target antigens,the types of cytotoxic small molecules,and the coupling strategy of linkers,summarizes and analyzes the development trend of ADC,providing reference for teaching and scientific research.

关 键 词：抗体-药物偶联物 单克隆抗体 靶点抗原 细胞毒性小分子 连接子 发展趋势 

分 类 号：R73[医药卫生—肿瘤] R979.1[医药卫生—临床医学]